826 related articles for article (PubMed ID: 29225305)
41. New therapeutic approaches in Alzheimer's disease.
Barcikowska M
Folia Neuropathol; 2004; 42(4):251-5. PubMed ID: 15679044
[TBL] [Abstract][Full Text] [Related]
42. Alzheimer's disease drug development based on Computer-Aided Drug Design.
Zeng H; Wu X
Eur J Med Chem; 2016 Oct; 121():851-863. PubMed ID: 26415837
[TBL] [Abstract][Full Text] [Related]
43. Therapeutic approaches to Alzheimer's disease through stimulating of non-amyloidogenic processing of amyloid precursor protein.
Wang YQ; Qu DH; Wang K
Eur Rev Med Pharmacol Sci; 2016 Jun; 20(11):2389-403. PubMed ID: 27338066
[TBL] [Abstract][Full Text] [Related]
44. Pharmacological evidences for DFK167-sensitive presenilin-independent gamma-secretase-like activity.
Sevalle J; Ayral E; Hernandez JF; Martinez J; Checler F
J Neurochem; 2009 Jul; 110(1):275-83. PubMed ID: 19457123
[TBL] [Abstract][Full Text] [Related]
45. Pharmacological modulation of GSAP reduces amyloid-β levels and tau phosphorylation in a mouse model of Alzheimer's disease with plaques and tangles.
Chu J; Lauretti E; Craige CP; Praticò D
J Alzheimers Dis; 2014; 41(3):729-37. PubMed ID: 24662099
[TBL] [Abstract][Full Text] [Related]
46. New developments in mild cognitive impairment and Alzheimer's disease.
Schott JM; Kennedy J; Fox NC
Curr Opin Neurol; 2006 Dec; 19(6):552-8. PubMed ID: 17102693
[TBL] [Abstract][Full Text] [Related]
47. Therapeutic strategies for Alzheimer's disease.
Barten DM; Albright CF
Mol Neurobiol; 2008; 37(2-3):171-86. PubMed ID: 18581273
[TBL] [Abstract][Full Text] [Related]
48. Amyloid-β protein (Aβ) Glu11 is the major β-secretase site of β-site amyloid-β precursor protein-cleaving enzyme 1(BACE1), and shifting the cleavage site to Aβ Asp1 contributes to Alzheimer pathogenesis.
Deng Y; Wang Z; Wang R; Zhang X; Zhang S; Wu Y; Staufenbiel M; Cai F; Song W
Eur J Neurosci; 2013 Jun; 37(12):1962-9. PubMed ID: 23773065
[TBL] [Abstract][Full Text] [Related]
49. Proteolytic processing of the Alzheimer's disease amyloid precursor protein in brain and platelets.
Evin G; Zhu A; Holsinger RM; Masters CL; Li QX
J Neurosci Res; 2003 Nov; 74(3):386-92. PubMed ID: 14598315
[TBL] [Abstract][Full Text] [Related]
50. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
[TBL] [Abstract][Full Text] [Related]
51. Potential treatment opportunities for Alzheimer's disease through inhibition of secretases and Abeta immunization.
Schenk D; Games D; Seubert P
J Mol Neurosci; 2001 Oct; 17(2):259-67. PubMed ID: 11816797
[TBL] [Abstract][Full Text] [Related]
52. Selective neutralization of APP-C99 with monoclonal antibodies reduces the production of Alzheimer's Aβ peptides.
Houacine J; Bolmont T; Aeschbach L; Oulad-Abdelghani M; Fraering PC
Neurobiol Aging; 2012 Nov; 33(11):2704-14. PubMed ID: 22317957
[TBL] [Abstract][Full Text] [Related]
53. TgCRND8 amyloid precursor protein transgenic mice exhibit an altered gamma-secretase processing and an aggressive, additive amyloid pathology subject to immunotherapeutic modulation.
Van Vickle GD; Esh CL; Kalback WM; Patton RL; Luehrs DC; Kokjohn TA; Fifield FG; Fraser PE; Westaway D; McLaurin J; Lopez J; Brune D; Newel AJ; Poston M; Beach TG; Roher AE
Biochemistry; 2007 Sep; 46(36):10317-27. PubMed ID: 17705508
[TBL] [Abstract][Full Text] [Related]
54. Diverse molecular targets for therapeutic strategies in Alzheimer's disease.
Han SH; Mook-Jung I
J Korean Med Sci; 2014 Jul; 29(7):893-902. PubMed ID: 25045220
[TBL] [Abstract][Full Text] [Related]
55. Connecting the Dots: Linking the Biochemical to Morphological Transitions in Alzheimer's Disease.
Baig AM
ACS Chem Neurosci; 2019 Jan; 10(1):21-24. PubMed ID: 30160095
[TBL] [Abstract][Full Text] [Related]
56. Characterization of FRM-36143 as a new γ-secretase modulator for the potential treatment of familial Alzheimer's disease.
Blain JF; Bursavich MG; Freeman EA; Hrdlicka LA; Hodgdon HE; Chen T; Costa DE; Harrison BA; Kapadnis S; Murphy DA; Nolan S; Tu Z; Tang C; Burnett DA; Patzke H; Koenig G
Alzheimers Res Ther; 2016 Aug; 8(1):34. PubMed ID: 27572246
[TBL] [Abstract][Full Text] [Related]
57. Pharmacotherapeutic targets in Alzheimer's disease.
Biran Y; Masters CL; Barnham KJ; Bush AI; Adlard PA
J Cell Mol Med; 2009 Jan; 13(1):61-86. PubMed ID: 19040415
[TBL] [Abstract][Full Text] [Related]
58. Quantitative pharmacokinetic/pharmacodynamic analyses suggest that the 129/SVE mouse is a suitable preclinical pharmacology model for identifying small-molecule γ-secretase inhibitors.
Lu Y; Zhang L; Nolan CE; Becker SL; Atchison K; Robshaw AE; Pustilnik LR; Osgood SM; Miller EH; Stepan AF; Subramanyam C; Efremov I; Hallgren AJ; Riddell D
J Pharmacol Exp Ther; 2011 Dec; 339(3):922-34. PubMed ID: 21930801
[TBL] [Abstract][Full Text] [Related]
59. Alzheimer's Disease: Characterization of the Brain Sites of the Initial Tau Cytoskeletal Pathology Will Improve the Success of Novel Immunological Anti-Tau Treatment Approaches.
Rüb U; Stratmann K; Heinsen H; Seidel K; Bouzrou M; Korf HW
J Alzheimers Dis; 2017; 57(3):683-696. PubMed ID: 28269779
[TBL] [Abstract][Full Text] [Related]
60. [The mechanism of A beta production and its inhibition as a therapeutic strategy for the prevention of Alzheimer's disease].
Iwatsubo T
Nihon Yakurigaku Zasshi; 2002 Nov; 120(1):30P-33P. PubMed ID: 12491772
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
